US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
According to Jinse Finance, on Thursday, SuperX AI Technology (SUPX.US) saw its share price decline, dropping more than 2.5% at one point to hit an intraday low of $6.46. In related news, the company announced the launch of an upgraded version of its Artificial Intelligence Innovation Center (AIIC 2.0), featuring a new "Model as a Service" functionality. This allows enterprises to directly access deployed AI models without having to build and maintain their own model operating environments, thereby lowering the barriers for businesses to adopt artificial intelligence technology.
It is understood that the AIIC was jointly developed by SuperX and data center operator STTGDC. It was announced on April 15, 2026, at the STT Singapore 5 data center facility located in the Dadeng region of Singapore.
The newly added "Model as a Service" feature in AIIC 2.0 enables customers to use already deployed AI models directly through an Application Programming Interface (API). This means companies do not have to allocate computing resources or take responsibility for daily model maintenance, allowing them to integrate AI capabilities into their business systems with ease.
SuperX stated that the upgraded AIIC 2.0 will offer services to enterprises and institutions in Singapore and other Southeast Asian regions, supporting customers in testing and validating various AI applications and helping them gradually expand pilot projects to broader business scenarios.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Tobacco and alcohol stocks lead gains in the consumer staples sector
On October 8, Thursday, Philip Morris International (PM.N) became the top gainer in the S&P 500 Consumer Staples sector (.SPLRCS), followed by alcoholic beverage company Constellation Brands (STZ.N) and Altria Group (MO.N), both ranking among the day's biggest gainers. Shares of Philip Morris International (PM), a supplier of cigarettes and smoke-free nicotine products, rose about 4% to $200.89, set for a fourth consecutive session of gains and marking the largest single-day increase since July 16. Marlboro cigarette maker Altria gained 2.9% to $71.36. Earlier, British peer Imperial Brands (IMB.L) said it expects to meet its full-year guidance and announced a £1.5 billions ($1.98 billions) share buyback plan, as robust growth in tobacco alternatives helped offset declining cigarette sales. STZ, which produces beer, wine, and spirits, rose over 3% to $122.35 on the second trading day after releasing its quarterly report, despite several brokerages lowering their price targets. JPMorgan, however, raised its target from $133 to $136. Cetera Chief Investment Officer Gene Goldman noted on Thursday that there is “a rotation from growth stocks to defensive stocks” in the market, adding that “rising yields and wider credit spreads are putting pressure on AI and growth stocks.” He also pointed out that valuations in the sector are improving. Over the past three months, the sector has underperformed the broader S&P 500, falling 1% versus the benchmark’s 3.9% rise. Among the five S&P sectors that did not decline on Thursday, the Consumer Staples Index posted the second-largest gain, up 1.6%.
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
